ARID1A and hepatocellular carcinoma: Finally, 16.7% (5/30) and 10% (3/10) of patients presented mutations in AXIN1 on their cfDNA or HCC tissue, respectively, and mutations in ARID1A were found in 10% (3/30) and 6.7% (2/30) of patients in cfDNA and HCC tissue (Figure 4A).